Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-26-011492
Filing Date
2026-03-27
Accepted
2026-03-27 06:03:30
Documents
20
Period of Report
2026-05-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20064945x1_def14a.htm   iXBRL DEF 14A 1235276
4 ny20064945x1_pc01.jpg GRAPHIC 615652
5 ny20064945x1_pc02.jpg GRAPHIC 574242
6 ny20064945x1_piecharts0x1.jpg GRAPHIC 133376
7 ny20064945x1_pvpchart01x1.jpg GRAPHIC 188656
8 ny20064945x1_pvpchart02x1.jpg GRAPHIC 151998
9 sig_arthursands.jpg GRAPHIC 13771
10 sig_arthursandsx1.jpg GRAPHIC 16879
  Complete submission text file 0001140361-26-011492.txt   6507571

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA nrix-20260515.xsd EX-101.SCH 3233
3 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE nrix-20260515_lab.xml EX-101.LAB 2923
23 EXTRACTED XBRL INSTANCE DOCUMENT ny20064945x1_def14a_htm.xml XML 246148
Mailing Address 1600 SIERRA POINT PKWY BRISBANE CA 94005
Business Address 1600 SIERRA POINT PKWY BRISBANE CA 94005 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: DEF 14A | Act: 34 | File No.: 001-39398 | Film No.: 26800734
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)